Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, with its lead ...

Fintel reports that on January 29, 2025, Truist Securities initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a ...

Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.

Truist analyst Joon Lee initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Invest with Confidence: Follow ...

As previously reported, Truist initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Despite “promising” ...

HC Wainwright reissued their buy rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $15.00 target ...

Four Philly-area CEOs discuss how they got to their positions, who helped along the way, and tips for others forging the path ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases ...

Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), a clinical-stage pharmaceutical company with a market capitalization of $221 million, has issued performance-based restricted stock units (PSUs ...